• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Biotechnol . LAMP-Seq enables sensitive, multiplexed COVID-19 diagnostics using molecular barcoding

tetano

Editor, Senior Moderator
Nat Biotechnol


. 2021 Jun 29.
doi: 10.1038/s41587-021-00966-9. Online ahead of print.
LAMP-Seq enables sensitive, multiplexed COVID-19 diagnostics using molecular barcoding


Kerstin U Ludwig[SUP] 1 [/SUP], Ricarda M Schmithausen[SUP] 2 [/SUP], David Li[SUP] 3 4 5 6 [/SUP], Max L Jacobs[SUP] 7 8 [/SUP], Ronja Hollstein[SUP] 1 [/SUP], Katja Blumenstock[SUP] 7 [/SUP], Jana Liebing[SUP] 9 [/SUP], Mikołaj Słabicki[SUP] 3 10 11 [/SUP], Amir Ben-Shmuel[SUP] 12 [/SUP], Ofir Israeli[SUP] 13 [/SUP], Shay Weiss[SUP] 12 [/SUP], Thomas S Ebert[SUP] 7 [/SUP], Nir Paran[SUP] 12 [/SUP], Wibke Rüdiger[SUP] 7 [/SUP], Gero Wilbring[SUP] 2 [/SUP], David Feldman[SUP] 14 [/SUP], Bärbel Lippke[SUP] 1 [/SUP], Nina Ishorst[SUP] 1 15 [/SUP], Lara M Hochfeld[SUP] 1 [/SUP], Eva C Beins[SUP] 1 [/SUP], Ines H Kaltheuner[SUP] 16 [/SUP], Maximilian Schmitz[SUP] 16 [/SUP], Aliona Wöhler[SUP] 17 [/SUP], Manuel Döhla[SUP] 2 18 [/SUP], Esther Sib[SUP] 2 [/SUP], Marius Jentzsch[SUP] 7 [/SUP], Jacob D Borrajo[SUP] 3 6 [/SUP], Jonathan Strecker[SUP] 3 4 5 6 [/SUP], Julia Reinhardt[SUP] 9 [/SUP], Brian Cleary[SUP] 3 [/SUP], Matthias Geyer[SUP] 16 [/SUP], Michael Hölzel[SUP] 9 [/SUP], Rhiannon Macrae[SUP] 3 4 5 6 [/SUP], Markus M Nöthen[SUP] 1 [/SUP], Per Hoffmann[SUP] 1 19 [/SUP], Martin Exner[SUP] 2 [/SUP], Aviv Regev[SUP] 3 20 21 22 23 24 [/SUP], Feng Zhang[SUP] 3 4 5 6 23 [/SUP], Jonathan L Schmid-Burgk[SUP] 25 26 27 28 29 [/SUP]



Affiliations

Abstract

Frequent testing of large population groups combined with contact tracing and isolation measures will be crucial for containing Coronavirus Disease 2019 outbreaks. Here we present LAMP-Seq, a modified, highly scalable reverse transcription loop-mediated isothermal amplification (RT-LAMP) method. Unpurified biosamples are barcoded and amplified in a single heat step, and pooled products are analyzed en masse by sequencing. Using commercial reagents, LAMP-Seq has a limit of detection of ~2.2 molecules per µl at 95% confidence and near-perfect specificity for severe acute respiratory syndrome coronavirus 2 given its sequence readout. Clinical validation of an open-source protocol with 676 swab samples, 98 of which were deemed positive by standard RT-qPCR, demonstrated 100% sensitivity in individuals with cycle threshold values of up to 33 and a specificity of 99.7%, at a very low material cost. With a time-to-result of fewer than 24 h, low cost and little new infrastructure requirement, LAMP-Seq can be readily deployed for frequent testing as part of an integrated public health surveillance program.
 
Back
Top Bottom